Targeting therapy of hepatocellular carcinoma with doxorubicin prodrug PDOX increases anti-metastatic effect and reduces toxicity: a preclinical study

BACKGROUND: This study was to investigate the effects and safety of cathepsin B-cleavable doxorubicin (DOX)-prodrug (PDOX) for targeting therapy of metastatic human hepatocellular carcinoma (HCC) using DOX as a positive control drug. METHODS: The orthotopic nude mice model of highly metastatic HCC w...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Qun, Zhong, Yan-Jun, Yuan, Jing-Ping, Shao, Li-Hua, Zhang, Jue, Tang, Li, Liu, Shao-Ping, Hong, Ya-Ping, Firestone, Raymond A, Li, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3765954/
https://www.ncbi.nlm.nih.gov/pubmed/23961994
http://dx.doi.org/10.1186/1479-5876-11-192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3765954/
https://www.ncbi.nlm.nih.gov/pubmed/23961994
http://dx.doi.org/10.1186/1479-5876-11-192

Ejemplares similares